EUCTR2016-002347-41-DE进行中（未招募）1 期
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation - CheckMate 744
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Classic Hodgkin Lymphoma (cHL), relapsed or refractory
- •Minimal limitation on activities of daily living as measured by Karnofsky = 50 for participants > 16 years of age or Lansky = 50 for participants = 16 years of age.
- •One prior anti-cancer therapy that did not work
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 48
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Active, known, or suspected autoimmune disease or infection
- •Active cerebral/meningeal disease related to the underlying malignancy
- •More than one line of anti-cancer therapy or no treatment at all
- •Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
- •Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 19.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-NLBristol-Myers Squibb International Corporation80
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO80
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 19.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-ESBristol-Myers Squibb International Corporation80
招募中
2 期
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.10025319Hodgkin LymphomaLymphomaNL-OMON53072Bristol-Myers Squibb4
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-GBBristol-Myers Squibb International Corporation80